PF-06747775 + avelumab

**PF-06747775 + avelumab** is an experimental combination therapy investigated for advanced non-small cell lung cancer (NSCLC) with EGFR mutations, including the secondary T790M mutation. PF-06747775 is an oral, third-generation, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to inhibit both activating and resistance (T790M) mutations in EGFR. Avelumab is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), acting as an immune checkpoint inhibitor to enhance T-cell-mediated anti-tumor response. The rationale for combining these agents is to achieve better anti-tumor efficacy through dual targeting of oncogenic signaling and tumor immune evasion pathways. The combination was evaluated in a Phase 1b/2 multi-cohort study to determine safety, tolerability, dosing, and preliminary efficacy in patients with EGFR-mutated NSCLC that progressed after prior EGFR TKI therapy[1][3][5].

Brand names

Bavencio

Other names

PF-06747775PF06747775PF 06747775avelumabBavencio